Semaglutide efficiency in BWR was evaluated in both doses of 1 mg (approved for T2DM) and 2.4 mg (approved for obesity) in a STEP-2 trial, and 68.8% of subjects achieved a BWR ≥ 5% from the V0M, but insulin was notably not used in patients [43]. This evidence concerns the gene INS and obesity disorder.